NCT01849887

Safety of Escalating Doses of Intravenous Bone Marrow-Derived Mesenchymal Stem Cells in Patients With a New Ischemic Stroke

• Status: Withdrawn
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: University of California, Irvine · Academic / Other
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

Stroke is a major cause of adult disability. Currently approved reperfusion therapies are provided to only a small percentage of patients in the U.S. New therapies are needed that improve outcome and that can be accessed by a majority of patients. Animal studies suggest that bone marrow-derived mesenchymal stem cells, administered intravenously days after a stroke, safely improve long-term behavioral outcome. A large human experience suggests the safety of allogeneic bone marrow-derived mesenchymal stem cells. The current study aims to assess the safety of this therapy in patients with recent ischemic stroke.

Conditions

• Ischemic Stroke

Interventions

Type	Name	Description
BIOLOGICAL	bone marrow-derived mesenchymal stem cells	bone marrow-derived mesenchymal stem cells
DRUG	Placebo	Placebo

Timeline

• Start date: 2016-01-01
• Primary completion: 2016-01-01
• Completion: 2016-01-01
• First posted: 2013-05-09
• Last updated: 2016-01-22

Locations

1 site across 1 country: United States